Generic Name and Formulations:
Glimepiride 1mg, 2mg, 4mg; scored tabs.
Indications for AMARYL:
Adjunct to diet and exercise in type 2 diabetes mellitus. Limitations of use: not for the treatment of type 1 diabetes or ketoacidosis.
Initially 1–2mg once daily with breakfast or first main meal; after reaching a dose of 2mg, may further increase by 1–2mg at 1–2 week intervals if needed; max 8mg/day. Increased risk of hypoglycemia (eg, elderly or renal impairment): initially 1mg once daily, titrate carefully.
Renal or hepatic impairment. Adrenal or pituitary insufficiency. Risk of hemolytic anemia in G6PD deficiency; consider non-sulfonylurea alternative. Increased risk of cardiovascular mortality. Discontinue if hypersensitivity reaction is suspected. Elderly. Debilitated. Malnourished. Pregnancy (Cat.C): consider using insulin instead. Nursing mothers: not recommended.
May be potentiated by pramlintide acetate, insulin, ACE inhibitors, H2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, NSAIDs, highly protein bound drugs (eg, fluoxetine), oral miconazole (possibly), salicylates, sulfonamides, warfarin, chloramphenicol, probenecid, MAOIs. May be antagonized by danazol, glucagon, somatotropin, protease inhibitors, atypical antipsychotics, barbiturates, diazoxide, laxatives, rifampin, thiazides, diuretics, corticosteroids, phenothiazines, thyroid products, phenytoin, niacin, sympathomimetics, isoniazid, estrogens, oral contraceptives. Monitor closely for hypoglycemia when concomitant drugs that affect glucose metabolism and upon withdrawal. Caution with CYP2C9 inhibitors (eg, fluconazole) or inducers (eg, rifampin). May be potentiated or antagonized by β-blockers, clonidine, reserpine, alcohol. May be antagonized by colesevelam; administer glimepiride ≥4hrs prior to colesevelam. Disulfiram reactions have been reported with other sulfonylureas. Monitor for 1–2 weeks if transferring from long-acting sulfonylureas.
Sulfonylurea (2nd generation).
Hypoglycemia, headache, nausea, dizziness, weight gain; allergic skin reactions, hemolytic anemia.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Prevalence of ADHD Relatively Stable Over Time Despite Increase in Diagnoses
- Prevalence of Major Depressive Disorder Remains High In US Population
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Evidence of Methylphenidate Abuse: Characterizing Patterns of Use in Pediatric and Adult Populations
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- Most Patients Comfortable With Clinicians Asking About Sexual Orientation
- Peer-to-Peer Depression Awareness Program May Be Beneficial
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders